Article
Early Mucosal Type II Interferon Limits SARS-CoV-2 Replication in Humans
2026-07-01
Abstract excerpt
<h4>ABSTRACT</h4> COVID-19 vaccines markedly reduce disease severity, but their ability to block infection and transmission remains limited and variable. 1 A better understanding of early mucosal immune programs that constrain viral replication at susceptible upper respiratory sites is needed to develop more effective antiviral strategies. However, temporal and anatomical antiviral dynamics are difficult to reso...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 305608c1-e983-5249-a28e-89715c85a92d
- DOI
- 10.64898/2026.06.29.26356894
